Core Scientific (NASDAQ:CORZ) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 5.88 percent. This is a 60 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $78.628 million which missed the analyst consensus estimate of $80.765 million by 2.65 percent. This is a 44.28 percent decrease over sales of $141.102 million the same period last year.